Showing papers by "Barbara J. Stoll published in 1996"

Interlaboratory variability of bilirubin measurements.

Abstract: During an 8-month study, 14 laboratories used automated analytical systems to measure total bilirubin concentrations in lyophilized bovine specimens containing 38, 169, and 253 micromol/L bilirubin (2.2, 9.9, and 14.8 mg/dL, respectively). The measured mean +/- SD (n, range) were: 39 +/- 7 micromol/L (n = 90, 31-53) [2.3 +/- 0.4 mg/dL (1.8-3.1)]; 176 +/- 29 micromol/L (n = 89, 146-222) [10.3 +/- 1.7 mg/dL (8.5-13.0)]; and 260 +/- 43 micromol/L (n = 103, 208-316) [15.2 +/- 2.5 mg/dL (12.1-18.5)]. In comparison with target values, measurements were consistently lower at 4, higher at 6, and within +/- 4% at 4 laboratories for each of the three concentrations. The measured values for each concentration remained fairly constant during the study at each laboratory. We conclude that bilirubin measurements differed significantly from the established target values at most of the participating laboratories.

Anisoosmotic regulation of hepatic gene expression.

Abstract: The effect of anisoosmolarity on the abundance of various mRNA species was examined in perfused rat liver and H4IIE rat hepatoma cells. Hyperosmotic exposure (385 mosmol/l) of isolated rat livers increased mRNA levels for tyrosine aminotransferase (TAT) by 246% and those for phosphoenolpyruvate carboxykinase (PEPCK) by 186%, whereas hypoosmotic exposure (225 mosmol/l) decreased their levels to 43% and 42%, respectively. mRNA levels for fructose-1,6-bisphosphatase (FBP), argininosuccinate lyase (ASL), argininosuccinate synthetase (ASS), glutamine synthetase (GS), glutaminase (GA) and glucokinase (GK) were largely unaffected. In H4IIE cells the modulation of TAT and PEPCK mRNA levels by anisoosmotic exposure was similar to that found in perfused rat liver. ASL and glutaminase mRNA levels were influenced in an opposite manner. The effects of anisoosmolarity on PEPCK mRNA levels in H4IIE cells were largely abolished in the presence of the protein kinase inhibitors H-7, H-89 and HA-1004. Other protein kinase inhibitors such as Go-6850, KN-62, Rp-8-CPT-cAMPS, rapamycin, wortmannin, genistein or herbimycin did not prevent the osmosensitivity of PEPCK mRNA levels. Also pertussis and cholera toxin, vanadate and colchicine did not affect the osmosensitivity of PEPCK mRNA levels. The data suggest that anisoosmotic exposure acts on the levels of some but not all mRNA species and that this action may involve changes in protein phosphorylation. They further indicate that the recently identified osmosensitive signal transduction pathway which involves a G-protein and tyrosine kinase dependent activation of mitogen-activated protein kinases is apparently not involved in the osmoregulation of PEPCK mRNA levels.

Dexamethasone therapy in infants at risk for chronic lung disease(cld): a multi-center, randomized, double-masked trial • 1399

Abstract: DEXAMETHASONE THERAPY IN INFANTS AT RISK FOR CHRONIC LUNG DISEASE(CLD): A MULTI-CENTER, RANDOMIZED, DOUBLE-MASKED TRIAL • 1399

In utero magnesium exposure: risk of death and of intraventricular hemorrhage (ivh) in very low birth weight (vlbw) infants. • 1336

Abstract: IN UTERO MAGNESIUM EXPOSURE: RISK OF DEATH AND OF INTRAVENTRICULAR HEMORRHAGE (IVH) IN VERY LOW BIRTH WEIGHT (VLBW) INFANTS. • 1336

Neonatal mortality and morbidities in very low birth weight (vlbw) infants: a seven-year trend analysis of the neonatal research network data. † 1392

Abstract: NEONATAL MORTALITY AND MORBIDITIES IN VERY LOW BIRTH WEIGHT (VLBW) INFANTS: A SEVEN-YEAR TREND ANALYSIS OF THE NEONATAL RESEARCH NETWORK DATA. † 1392

Impact of the nih consensus development conference on corticosteroids for fetal maturation: increased antenatal steroid use in nichd network vlbw infants. † 1507

Abstract: We have previously reported that less than 20% of eligible VLBW infants receive antenatal steroid (ANS) treatment. The purpose of this analysis was to compare the rates of ANS therapy and characteristics of women treated with ANS in the Network before and after the Consensus Development Conference (CDC), 2/28/94. ANS treatment of mothers of VLBW infants in the 34 mos before (n = 7610) and the 16 mos after the CDC (n = 3151) were compared. Overall, ANS use increased from 20.6% (center range 1-39%) to 45.9% (27-66%); during the latest available 4-mo period, 55% of VLBW mothers were treated. During both periods patients with prenatal care, multiple gestation, hypertension/preeclampsia, diabetes, c-section, tocolytics or antibiotics were more likely (OR 1.09- 4.58) and those with antepartum hemorrhage or labor were less likely (OR 0.62- 0.76) to receive ANS. Patients with PROM and prolonged ROM were less likely before the CDC (OR 0.74 and 0.76, respectively) and more likely after the CDC(OR 1.66 and 1.87, respectively) to receive ANS. The OR for ANS plus antibiotics increased from 1.86 to 3.78 post CDC. ANS increased approximately 2-fold in all GA groups after the CDC: Table

Predicting neonatal mortality and morbidity: utility of the crib score.† 1628

Abstract: The CRIB score (CS) is a risk-adjustment statistical model derived from minimum and maximum FiO2, maximum base deficit and congenital malformation data, as well as gestational age (GA) and birthweight (BW). In the UK CS at≤ 12 hrs of age has been proposed as a better predictor of neonatal mortality (Mort) and morbidity than BW alone.